177 related articles for article (PubMed ID: 28639315)
1. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.
Wang WG; Liu ZB; Jiang XN; Lee J; Zhou XY; Li XQ
Histopathology; 2017 Nov; 71(5):778-785. PubMed ID: 28639315
[TBL] [Abstract][Full Text] [Related]
2. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
[TBL] [Abstract][Full Text] [Related]
3. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features.
Wang WG; Cui WL; Wang L; Zhu F; Wan XC; Ping B; Zhou XY; Li XQ
Am J Surg Pathol; 2015 Jul; 39(7):902-11. PubMed ID: 25970684
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
Wang WG; Jiang XN; Sheng D; Sun CB; Lee J; Zhou XY; Li XQ
Lab Invest; 2019 Oct; 99(10):1418-1427. PubMed ID: 31197205
[TBL] [Abstract][Full Text] [Related]
5. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.
Bogusz AM; Baxter RH; Currie T; Sinha P; Sohani AR; Kutok JL; Rodig SJ
Clin Cancer Res; 2012 Nov; 18(22):6122-35. PubMed ID: 22966017
[TBL] [Abstract][Full Text] [Related]
6. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
[TBL] [Abstract][Full Text] [Related]
7. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Moyo TK; Wilson CS; Moore DJ; Eischen CM
Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
9. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.
Dunleavy K; Erdmann T; Lenz G
Cancer Treat Rev; 2018 Apr; 65():41-46. PubMed ID: 29549872
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.
Bogusz AM; Kovach AE; Le LP; Feng D; Baxter RH; Sohani AR
PLoS One; 2017; 12(2):e0172364. PubMed ID: 28212447
[TBL] [Abstract][Full Text] [Related]
11. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
Xue T; Wang WG; Zhou XY; Li XQ
Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
[TBL] [Abstract][Full Text] [Related]
12. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
13. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
14. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
15. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
[TBL] [Abstract][Full Text] [Related]
16. The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.
Psathas JN; Doonan PJ; Raman P; Freedman BD; Minn AJ; Thomas-Tikhonenko A
Blood; 2013 Dec; 122(26):4220-9. PubMed ID: 24169826
[TBL] [Abstract][Full Text] [Related]
17. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE
Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116
[TBL] [Abstract][Full Text] [Related]
18. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
[TBL] [Abstract][Full Text] [Related]
20. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
